Literature DB >> 35834132

Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter.

Gianluca Businello1, Valentina Angerilli1, Sara Lonardi2, Francesca Bergamo2, Michele Valmasoni3, Fabio Farinati3, Edoardo Savarino3, Gaya Spolverato3, Matteo Fassan4,5.   

Abstract

The comprehensive molecular characterization of gastric and gastroesophageal junction adenocarcinomas has led to the improvement of targeted and more effective treatments. As a result, several biomarkers have been introduced into clinical practice and the implementation of innovative diagnostic tools is under study. Such assessments are mainly based on the evaluation of limited biopsy material in clinical practice. In this setting, the pathologist represents a key player in the selection of patients facilitating precision medicine approaches.
© 2022. The Author(s).

Entities:  

Keywords:  Biomarkers; Gastric adenocarcinoma; Gastroesophageal junction adenocarcinoma; Immunohistochemistry

Year:  2022        PMID： 35834132     DOI： 10.1007/s13304-022-01330-5

Source DB:  PubMed          Journal:  Updates Surg        ISSN： 2038-131X


  105 in total

1.  THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION.

Authors:  P LAUREN
Journal:  Acta Pathol Microbiol Scand       Date:  1965

Review 2.  Causes and consequences of microsatellite instability in gastric carcinogenesis.

Authors:  Sérgia Velho; Maria Sofia Fernandes; Marina Leite; Ceu Figueiredo; Raquel Seruca
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

3.  Age-specific trends in incidence of noncardia gastric cancer in US adults.

Authors:  William F Anderson; M Constanza Camargo; Joseph F Fraumeni; Pelayo Correa; Philip S Rosenberg; Charles S Rabkin
Journal:  JAMA       Date:  2010-05-05       Impact factor: 56.272

4.  Is gastric cancer part of the tumour spectrum of hereditary non-polyposis colorectal cancer? A molecular genetic study.

Authors:  A Gylling; W M Abdel-Rahman; M Juhola; K Nuorva; E Hautala; H J Järvinen; J-P Mecklin; M Aarnio; P Peltomäki
Journal:  Gut       Date:  2007-01-31       Impact factor: 23.059

5.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

Review 6.  Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux.

Authors:  J H Rubenstein; J B Taylor
Journal:  Aliment Pharmacol Ther       Date:  2010-09-23       Impact factor: 8.171

Review 7.  Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives.

Authors:  Antonio Pellino; Erika Riello; Floriana Nappo; Stefano Brignola; Sabina Murgioni; Selma Ahcene Djaballah; Sara Lonardi; Vittorina Zagonel; Massimo Rugge; Fotios Loupakis; Matteo Fassan
Journal:  World J Gastroenterol       Date:  2019-10-14       Impact factor: 5.742

Review 8.  Precancerous lesions of the stomach, gastric cancer and hereditary gastric cancer syndromes.

Authors:  Irene Gullo; Federica Grillo; Luca Mastracci; Alessandro Vanoli; Fatima Carneiro; Luca Saragoni; Francesco Limarzi; Jacopo Ferro; Paola Parente; Matteo Fassan
Journal:  Pathologica       Date:  2020-09

Review 9.  Current prognostic and predictive biomarkers for gastrointestinal tumors in clinical practice.

Authors:  Matteo Fassan; Aldo Scarpa; Andrea Remo; Giovanna De Maglio; Giancarlo Troncone; Antonio Marchetti; Claudio Doglioni; Giuseppe Ingravallo; Giuseppe Perrone; Paola Parente; Claudio Luchini; Luca Mastracci
Journal:  Pathologica       Date:  2020-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.